

Serum Platelet Factor 4 Is an Independent Predictor of Survival and Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma

Katherine E. Poruk¹, Matthew A. Firpo^{1,5}, Luke M. Huerter², Courtney L. Scaife^{1,5}, Lyska L. Emerson³, Kenneth M. Boucher^{4,5}, Kimberly A. Jones^{2,5}, and Sean J. Mulvihill^{1,5}

Abstract

Background: Improved diagnostic, predictive, and prognostic biomarkers for pancreatic ductal adenocarcinoma (PDAC) are urgently needed. Platelet factor 4 (PF4) has been proposed as a diagnostic biomarker for PDAC. We assessed the diagnostic and prognostic potential of serum PF4 levels in PDAC patients.

Methods: Serum PF4 levels were determined by enzyme-linked immunosorbent assay in an initial cohort of 62 PDAC patients, 62 healthy control subjects, and 34 chronic pancreatitis patients. A second validation set consisted of 71 PDAC patients. Linear regression models were used to relate PF4 to class, gender, age, stage, platelet count, and diagnosis. Survival analyses were done using univariate and multivariate Cox models.

Results: In the initial cohort, serum PF4 levels distinguished PDAC from chronic pancreatitis patients ($P = 0.011$), but not from healthy control subjects ($P = 0.624$). In PDAC patients, high serum PF4 level significantly predicted decreased survival independent of all covariates examined ($P < 0.01$). The prognostic relationship of serum PF4 levels remained significant in the validation set. Venous thromboembolism (VTE) occurred in 20% of the 133 PDAC patients. The VTE risk was higher in subjects with elevated PF4 levels ($P = 0.009$).

Conclusions: Serum PF4 is shown for the first time to be prognostic for survival in PDAC patients. High PF4 is associated with an increased risk for the development of VTE.

Impact: Serum PF4 levels may be useful for patient stratification and for directing treatment options in patients with pancreatic cancer including anticoagulation prophylaxis. The relationship between high PF4 levels and poorer outcomes requires further study. *Cancer Epidemiol Biomarkers Prev*; 19(10); 2605–10. ©2010 AACR.

Introduction

Although pancreatic cancer comprises only 3% of estimated new cancer cases, it is the fourth most common cause of cancer mortality in the United States (1). The 5-year survival rate for patients with pancreatic ductal adenocarcinoma (PDAC) is only about 5% for all stages, with a survival rate of about 20% in patients with local disease and 2% in patients with distant metastases (2). PDAC typically develops with few symptoms and only a minority of cases are diagnosed at an early stage. When symptoms such as weight loss, abdominal pain, and jaundice do occur, distant metastases are often present, precluding treatment for cure. Surgery remains the only potentially curative treatment, but most patients recur and succumb to the disease despite resection. Optimal

treatment strategies for patients with pancreatic cancer are still evolving and largely target the malignancy, although therapies that treat tumor-driven complications can decrease morbidity and prolong survival. Venous thromboembolism (VTE), for example, is highly associated with PDAC and preventative strategies are evolving (3, 4). Neoadjuvant treatment has the potential to improve outcome for patients undergoing surgical resection (5), and postoperative adjuvant therapy has been shown to improve survival and delay the development of recurrent disease after resection (6). However, only relatively primitive consensus selection criteria for these therapies have been developed. Thus, there is a need for biomarkers that will (a) allow for early identification of patients with pancreatic cancer while the disease is treatable for cure; (b) help differentiate patients with PDAC from those with chronic pancreatitis to ensure correct treatment; (c) optimally select patients for neoadjuvant therapy, surgical resection, and postoperative adjuvant therapy; and (d) predict outcome more accurately than stage alone.

Using mass spectrometry-based serum peptide profiling, a recent publication identified platelet factor 4 (PF4) as a potential biomarker for pancreatic cancer (7). This study showed that PF4 was significantly lower in serum

Authors' Affiliations: Departments of ¹Surgery, ²Internal Medicine, ³Pathology, and ⁴Oncological Sciences, University of Utah School of Medicine, and the ⁵Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

Corresponding Author: Matthew A. Firpo, Department of Surgery, 30 North 1900 East, Salt Lake City, UT 84132. Phone: 801-587-9049; Fax: 801-581-6612. E-mail: matt.firpo@hsc.utah.edu

doi: 10.1158/1055-9965.EPI-10-0178

©2010 American Association for Cancer Research.

from PDAC patients than in serum from healthy controls, whereas PF4 was statistically significantly higher in serum from patients with acute pancreatitis than in serum from PDAC patients. These results were verified using enzyme-linked immunosorbent assay (ELISA) to measure PF4 serum levels. In the current study, we proposed to validate the results of the previous study by determining if serum PF4 could distinguish between pancreatic cancer patients and healthy control subjects in an independent cohort. We extended the previous study by assessing if serum PF4 levels could distinguish between PDAC and chronic pancreatitis. We further assessed PF4 as a prognostic factor in predicting survival in patients with pancreatic cancer. Finally, we assessed a possible cause of decreased survival associated with elevated PF4 levels.

Materials and Methods

Serum samples were obtained from an initial 158 subjects, including 62 patients with histologically or cytologically confirmed PDAC, 62 healthy control subjects, and 34 chronic pancreatitis patients. A second group of 71 patients with confirmed PDAC were chosen as a validation cohort. PDAC subjects were selected based on certainty of the diagnosis of PDAC by pathologic evaluation, availability of complete clinical information (including cause of death), and adequate pretreatment blood samples. Three cases were censored in survival analyses due to causes of death other than cancer progression. Healthy control subjects were chosen to gender-match and age-

approximate the PDAC cases and were obtained from two sources. First, adults accompanying index patients to clinic visits were approached and screened. Second, excess sera from de-identified healthy controls were obtained from a large reference laboratory managed by the University of Utah Department of Pathology. Subject characteristics are summarized in Table 1.

PDAC cases were further stratified by stage, extent of metastatic dissemination (“class”), and treatment. In statistical models, stage IA, IB, and IIA cases were combined into a single group due to the paucity of these early-stage cases in the cohort. For the purposes of this discussion, stratification based on class refers to either node negative (N₀), node positive (N₁), or presence of distant metastases (M₁), independent of node status. The patient was considered to have treatment expected to affect survival if he or she had received either surgical resection and/or at least one full course of chemotherapy and/or radiation.

Blood was collected prior to the patient receiving treatment, separated into the serum component, and frozen in aliquots for subsequent analysis. Serologic PF4 measurements were done by ELISA (Asserchrom, Stago). The samples were diluted 1:2,500 and PF4 levels were measured according to the manufacturer's recommendations. Absorbance readings were compared with the calibration curve, and the dilution factor was accounted for by multiplying each value by 2.5 (2,500/1,000) to generate values in kU/mL. Stratified Kaplan-Meier curves were used to plot survival and compute median survival. The Cox model and logrank test were used for formal

Table 1. Subject characteristics

Subject group	Initial cohort		Validation cohort	
	Number of cases	Median age in years (range)	Number of cases	Median age in years (range)
Pancreatic ductal adenocarcinoma				
Total	62	68 (42-89)	71	65 (44-87)
Female	28	70 (43-89)	32	69.5 (44-87)
Male	34	65 (42-86)	39	62 (47-82)
Stage IA	1		3	
Stage IB	4		5	
Stage IIA	8		4	
Stage IIB	18		18	
Stage III	10		12	
Stage IV	21		29	
Healthy control				
Total	62	67.5 (42-94)		
Female	28	69 (43-94)		
Male	34	65 (43-83)		
Chronic pancreatitis				
Total	34	48.5 (29-81)		
Female	16	47.5 (30-63)		
Male	18	49.5 (29-81)		

Table 2. Relationship of serum PF4 to overall survival in PDAC subjects

Predictor	Stratification	Median survival in days (95% CI)	P*
Initial cohort			
PF4	Continuous (n = 62)	352 (310-411)	0.031
PF4	≤11 kU/mL (n = 31)	401 (345-918)	0.035
	>11 kU/mL (n = 31)	291 (174-400)	
Validation cohort			
PF4	Continuous (n = 71)	283 (227-402)	0.030
PF4	≤11 kU/mL (n = 34)	323 (275-681)	0.050
	>11 kU/mL (n = 37)	235 (170-370)	

Abbreviation: 95% CI, 95% confidence interval.

*Global P value by log-rank test.

survival analysis. Linear regression models were used to relate PF4 to class, gender, age, stage, platelet count, and diagnosis. P values < 0.05 were considered significant. All statistical analyses were done using the R version 2.8.0 statistical software (8).

Clinical charts of the 133 patients with PDAC were reviewed to determine the incidence of VTE after the date of the pretreatment serum sample, and included

pulmonary embolism, deep vein thrombosis, and splenic, mesenteric, and portal VTE. All VTE diagnoses were confirmed through imaging such as computed tomography or Doppler ultrasound. Platelet counts taken within one day of the research blood draw were also abstracted for each PDAC case.

All studies were carried out with the approval of the Institutional Review Board at the University of Utah.

Results

PF4 as a diagnostic biomarker

To assess diagnostic capabilities, serum PF4 levels were first measured in an initial cohort consisting of PDAC, chronic pancreatitis, and healthy control subjects. The median PF4 serum levels were 12.0 kU/mL (range, 0.4-20.4) in healthy control subjects, 11.1 kU/mL (1.3-25.8) in PDAC patients, and 8.9 kU/mL (1.2-22.1) in chronic pancreatitis patients. The difference between PF4 serum levels in patients with PDAC and the control group was not statistically significant (P = 0.62). However, the difference between PF4 serum levels in patients with chronic pancreatitis was significantly lower compared with either PDAC (P = 0.011) or the control group (P = 0.003).

PF4 as a prognostic biomarker

We next examined if PF4 correlated with survival in patients with PDAC. The median PF4 serum value in PDAC subjects, 11 kU/mL, was used as a discrete cutoff in the Cox model. Serum PF4 levels were a significant predictor of survival whether PF4 was used as a continuous (P = 0.031) or discrete (P = 0.035) variable (Table 2). Serum PF4 was inversely related to survival, with higher

Table 3. Univariate survival analysis

Predictor	Level	Median survival in days (95% CI)	Hazard ratio	P
PF4	Continuous (n = 133)	323 (283-385)	1.08	0.003
PF4*	≤11 kU/mL (n = 65)	389 (313-467)	1.00	—
	>11 kU/mL (n = 68)	254 (203-343)	1.77	0.004
Age	Continuous (n = 133)	323 (283-385)	1.024	0.005
Class*	N ₀ (n = 32)	401 (289-929)	—	—
	N ₁ (n = 51)	402 (336-455)	1.27	0.37
	M ₁ (n = 50)	170 (116-314)	2.85	<0.0001
Gender*	Female (n = 60)	254 (189-367)	—	—
	Male (n = 73)	374 (291-448)	0.61	0.013
Platelet Count	Continuous (n = 124)	323 (283-385)	0.23	0.82
Stage*	IA, I, IIA (n = 27)	401 (255-∞)	—	—
	IIB (n = 34)	402 (343-467)	1.50	0.19
	III (n = 23)	336 (283-∞)	1.53	0.20
	IV (n = 49)	170 (116-314)	3.22	<0.0001
Treatment*	No (n = 54)	283 (179-411)	—	—
	Yes (n = 76)	343 (291-400)	0.99	0.94

*Categorical variables were treated as ordered with the first level assigned as the reference.

Table 4. Correlation between serum PF4 and covariates

Covariate	Method	Correlation	n	P
Age	Pearson	-0.090	133	0.30
Class	Spearman	0.108	133	0.22
Gender	Spearman	-0.071	133	0.42
Platelet count*	Pearson	0.196	124	0.02
Stage	Spearman	0.125	133	0.15
Treatment [†]	Spearman	0.056	130	0.52

*Nine subjects with missing platelet count were not included.

[†]Three subjects with missing treatment information were not included.

PF4 levels corresponding to poorer prognosis. We then sought to validate the predictive effect of PF4 in a novel set of 71 patients with histologically or cytologically confirmed PDAC. Again, high PF4 significantly correlated with shorter survival time when using serum PF4 either as a continuous variable ($P = 0.030$) or as a discrete variable ($P = 0.050$) at the median threshold of 11 kU/mL identified in the initial cohort (Table 2). In the combined data set of 133 PDAC patients, those with PF4 serum levels below the threshold had a median survival of 389 days whereas those with levels above the threshold had a median survival of 254 days (Table 3), a difference of approximately 4.5 months.

In univariate survival analysis of the combined data set, the presence of distant metastasis (stage IV and its equivalent M₁ class), gender, and age were also significant predictors of survival, whereas survival was independent of platelet count or treatment (Table 3). Of the potential adjustment variables, the correlations with PF4 were minimal, and only platelet count was significantly related to the PF4 predictor (Table 4). None of the adjustment variables were significantly related to both PF4 levels and survival, and the contribution of serum PF4 to survival remained significant when adjusting for platelet counts alone ($P = 0.013$) or all predictors ($P = 0.01$) in multivariate models (data not shown).

Relationship of serum PF4 levels and VTE in PDAC patients

Given the potential coagulation-promoting function of PF4, the possibility that serum PF4 levels could predict increased risk for VTE was tested in our combined cohort. Overall, 27 of 133 PDAC subjects (20.3%) developed VTE. Cross-tabulation of VTE and serum PF4 levels showed a dramatic shift in the proportion of cases that went on to develop VTE in the high-PF4 group (Fig. 1) and indicated a 2.7-fold increased risk for development of VTE in cases with pretreatment serum PF4 levels >11 kU/mL. Using PF4 as a continuous variable also indicated a significant correlation between

pretreatment PF4 levels and the development of VTE ($P = 0.009$ by logistic regression). In univariate analysis, development of VTE was not significantly related to platelet count ($P = 0.28$), and PF4 remained a significant predictor of VTE development in multivariate analyses (Table 5).

Discussion

In our patient cohort, serum PF4 levels did not accurately distinguish between PDAC patients and normal healthy subjects, a finding contradictory to previously published results (7). The reasons behind this discrepancy are not immediately evident, although in both studies relatively small sample size and large group variances could have led to spurious differences. Institutional effects in which either self-selection or referral bias leads to differences in patient characteristics in the two institutions could also be a contributing factor in the discrepant findings. Serum PF4 levels did distinguish chronic pancreatitis patients from normal control subjects and PDAC patients in our cohort, suggesting that serum PF4 levels may have some diagnostic utility, particularly if combined in a panel with other biomarkers. Clinically, discrimination between chronic pancreatitis and PDAC is a typical diagnostic dilemma.

Importantly, our data show that serum PF4 level is a promising prognostic factor in patients with PDAC. In our cohort, PF4 was a robust predictor of survival independent of other predictors such as stage, class, and treatment. Because PF4 is stored in and released by platelets, it is possible that the changes in PF4 levels merely reflected changes in platelet counts. Indeed, in our cohort, serum PF4 levels and platelet counts were




Figure 1. High serum PF4 correlates with the development of VTE. PDAC patients were divided into two groups based on the detection of VTE. Each group was subdivided based on pretreatment serum PF4 levels using the 11 kU/mL threshold. Numbers above each bar, sample size for each group. A significantly higher proportion of patients with VTE had elevated pretreatment PF4 serum levels ($P = 0.009$ by Fisher's Exact Test).

Table 5. Multivariate analysis: PF4 predicting VTE

Predictor	Level	Model: PF4 + platelet only		Model: all predictors	
		Estimate*	P	Estimate*	P
PF4	Continuous	0.132	0.024	0.14	0.027
Platelet count	Continuous	0.0003	0.87	-0.0001	0.94
Age	Continuous	—	—	0.011	0.61
Class	N ₀ [†]	—	—	—	—
	N ₁	—	—	-0.88	0.39
	M ₁	—	—	-1.15	0.99
Gender	Female [†]	—	—	—	—
	Male	—	—	-0.079	0.97
Stage	IA, IB or IIA [†]	—	—	—	—
	IIB	—	—	0.62	0.62
	III	—	—	0.90	0.36
	IV	—	—	1.52	0.99
Treatment	No [†]	—	—	—	—
	Yes	—	—	0.0008	1.00

*Estimates are natural log odds.

[†]Categorical variables were treated as ordered with the first level assigned as the reference.

directly correlated (Table 4). However, the correlation was low (0.196), indicating that platelet counts could explain only about 4% of the variance in PF4 levels. Furthermore, platelet counts were not significantly related to survival (Table 3). These results suggest that PF4 either directly participates in or is an indicator of an underlying process occurring in some patients leading to poorer survival. PF4 is a CXC chemokine (CXCL4) present in α -granules of platelets at concentrations approximately 20,000 times higher than in the plasma (9, 10). The exact function of PF4 in normal physiology and in cancer is unknown. It is known, however, that PF4 is released upon platelet activation and binds to heparin-like molecules with high affinity, thus neutralizing the anticoagulant activity of heparin, suggesting a procoagulative function (11). Further, PF4-heparin complexes have been implicated as the target antigens in heparin-induced thrombocytopenia with thrombosis (12). PF4 is also one of a number of chemokines that have been variably found to either augment platelet activity and aggregation or fully initiate platelet adhesion, activation, and aggregation (13).

A procoagulative role for PF4 offers one possible explanation for the link between high serum PF4 levels and reduced survival. Pancreatic cancer cells are believed to activate platelets and other procoagulation factors, often leading to clinical manifestations such as deep vein thrombosis, pulmonary embolism, and disseminated intravascular coagulation (14). Development of VTE is a common complication of malignancy (4) and is associated with decreased survival (15, 16). In a study of 21 advanced pancreatic cancer patients, median survival was 8 months in those patients with

VTE as compared with 21 months for those without VTE (17). Thus, the presence of VTE seemingly indicates a worse prognosis in an already dismal form of cancer. Consistent with previously reported incidence rates (3, 18), 20% of PDAC cases developed VTE in our cohort. The increased risk for development of VTE in cases with high pretreatment serum PF4 suggests that PF4 predicts the onset of VTE in PDAC patients. The significance of this relationship persisted in multivariate analysis (Table 5), indicating that the link between PF4 and VTE could not be explained by differences in the covariates. Both surgery and chemotherapy are known to increase the incidence of VTE (4, 19, 20), whereas the procoagulant response is activated by radiotherapy (19). Of note, the multivariate model accounted for potential changes in VTE due to whether or not the patient received surgical, chemotherapeutic, or radiation treatment. The correlation between high PF4 levels and development of VTE may provide at least a partial explanation for the link between PF4 and survival rates, and suggests a method for the identification of patients that may benefit from prophylactic anticoagulation therapy.

One limitation of our study is that, as a retrospective review, the occurrence of VTE may have been underestimated. The prevalence of VTE in the patient cohort was established only if detected in the course of patient care and was not systematically assessed prospectively in each case. Furthermore, the contribution of VTE to cause of death was not addressed. That VTE, specifically pulmonary embolism, contributes to fatality was indicated in an autopsy series of 441 PDAC cases that showed a 42% incidence of pulmonary embolism at

the time of death, with pulmonary embolism listed as the immediate cause of death in 34% of cases (21). Prospective studies designed to address these shortcomings will be required to adequately establish the value of PF4 for predicting the development of life-threatening thromboembolic events.

In summary, our study identified serum PF4 as a strong independent predictor of survival and as being correlated with the development of VTE in PDAC patients. Serum PF4 levels may prove to be a valuable adjunct in identifying patients that may benefit from prophylactic antithrombotic therapy. Serum PF4 levels may help distinguish PDAC patients from those with chronic pancreatitis.

References

- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. *CA Cancer J Clin* 2009;59:225–49.
- Compton CC, Mulvihill SJ. Prognostic factors in pancreatic carcinoma. *Surg Oncol Clin N Am* 1997;6:533–54.
- Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. *Arch Intern Med* 2006;166:458–64.
- Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. *Lancet Oncol* 2005;6:401–10.
- Raut CP, Evans DB, Crane CH, Pisters PW, Wolff RA. Neoadjuvant therapy for resectable pancreatic cancer. *Surg Oncol Clin N Am* 2004;13:639–61, ix.
- Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. *JAMA* 2007;297:267–77.
- Fiedler GM, Leichle AB, Kase J, et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer. *Clin Cancer Res* 2009;15:3812–9.
- R-project.org [Internet]. Vienna, Austria: Institute for Statistics and Mathematics [updated 2010 May 31; cited 2010 July 15]. Available from: <http://www.r-project.org>.
- Kowalska MA, Rauova L, Poncz M. Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. *Thromb Res* 2010;125:292–6.
- Maurer AM, Zhou B, Han ZC. Roles of platelet factor 4 in hematopoiesis and angiogenesis. *Growth Factors* 2006;24:242–52.
- Clark-Lewis I, Dewald B, Geiser T, Moser B, Baggiolini M. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. *Proc Natl Acad Sci U S A* 1993;90:3574–7.
- Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. *Thromb Haemost* 1992;68:95–6.
- Al-Mondhry H. β -Thromboglobulin and platelet-factor 4 in patients with cancer: correlation with the stage of disease and the effect of chemotherapy. *Am J Hematol* 1983;14:105–11.
- Khorana AA, Fine RL. Pancreatic cancer and thromboembolic disease. *Lancet Oncol* 2004;5:655–63.
- Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. *N Engl J Med* 2000;343:1846–50.
- Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. *Cancer Invest* 2009;27 Suppl 1:63–74.
- Zawin M, Computaro C, Rahman Z, et al. Multirow detector CT detection of subclinical visceral and pulmonary thrombosis in advanced pancreatic cancer is an adverse prognostic indicator. *Proc Am Soc Clin Oncol* 2003;22:abstract 1419.
- Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. *Thromb Haemost* 2002;87:1076–7.
- Byrne M, Reynolds JV, O'Donnell JS, et al. Long-term activation of the pro-coagulant response after neoadjuvant chemoradiation and major cancer surgery. *Br J Cancer* 2010;102:73–9.
- Levine MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. *Thromb Haemost* 1997;78:133–6.
- Ogren M, Bergqvist D, Wahlander K, Eriksson H, Sternby NH. Trousseau's syndrome - what is the evidence? A population-based autopsy study. *Thromb Haemost* 2006;95:541–5.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

Research grants from the National Institutes of Health (R03 CA115225 to S.J. Mulvihill and P30CA042014 to the Huntsman Cancer Institute for support of core facilities). K.E. Poruk was supported in part by a Ruth L. Kirschstein National Research Service Award from the National Institutes of Health (T35HL07744).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 02/16/2010; revised 06/17/2010; accepted 07/12/2010; published OnlineFirst 08/20/2010.